BRIEF — Modus Therapeutics Temporarily Pauses Enrollment In Phase IIa Study Of Sevuparin In CKD With Anemia
Oct 15 (Reuters) — Modus Therapeutics Holding AB (publ): Said On Wednesday Voluntarily Decided, As A Precautionary Measure, To Temporarily Pause Enrollment In Part 2 Of The Ongoing Phase Iia Study Of Sevuparin Within The Co's Program In Ckd With Anemia The Decision Was Made After A Serious Adverse Event In A Patient Tr